Recent findings indicate CD169-positive lymph node sinus macrophages (LySMs) in the regional lymph nodes (RLNs) play an important role in anti-cancer immunity. In the present study, we investigated the correlation between CD169 expression in RLNs and clinicopathologic factors. Higher CD169 expression in LySMs was significantly associated with longer cancer-specific survival (CSS). The density of tumor-infiltrating lymphocytes (TILs) in the cancer nest and CD169 expression on LySMs were positively associated in patients who underwent pretreatment. As CD169 expression is thought to reflect a high interferon signature in RLNs, we tried to identify immunity-related genes that are up-regulated by interferon in macrophages as well as CD169. Indoleamine 2,3-dioxygenase (IDO1) was found to be elevated by interferon, and expression of IDO1 was tested using immunohistochemistry. IDO1 expression on LySMs was positively correlated with CD169 expression; however, there was no significant correlation between IDO1 and clinicopathologic factors. These results suggest that high expression of CD169 in LySMs reflects a high potential for anti-cancer immune responses in esophageal cancer patients and that monitoring CD169 expression would be useful for evaluating the potential of anticancer immune reactions.
Recent findings indicate CD169-positive lymph node sinus macrophages (LySMs) in the regional lymph nodes (RLNs) play an important role in anti-cancer immunity. In the present study, we investigated the correlation between CD169 expression in RLNs and clinicopathologic factors. Higher CD169 expression in LySMs was significantly associated with longer cancer-specific survival (CSS). The density of tumor-infiltrating lymphocytes (TILs) in the cancer nest and CD169 expression on LySMs were positively associated in patients who underwent pretreatment. As CD169 expression is thought to reflect a high interferon signature in RLNs, we tried to identify immunity-related genes that are up-regulated by interferon in macrophages as well as CD169. Indoleamine 2,3-dioxygenase (IDO1) was found to be elevated by interferon, and expression of IDO1 was tested using immunohistochemistry. IDO1 expression on LySMs was positively correlated with CD169 expression; however, there was no significant correlation between IDO1 and clinicopathologic factors. These results suggest that high expression of CD169 in LySMs reflects a high potential for anti-cancer immune responses in esophageal cancer patients and that monitoring CD169 expression would be useful for evaluating the potential of anticancer immune reactions.
Key words: CD169, CD8, esophageal cancer, lymph node, macrophage Esophageal cancer is one of the aggressive and lethal forms of cancer, and it is reportedly the eighth most common cancer. More than 450,000 patients with esophageal cancer are estimated as being newly diagnosed worldwide.
1,2 Esophageal cancer is a malignant tumor arising from the esophageal epithelium, and most common histologic type is squamous cell carcinoma (SCC), although the incidence of adenocarcinoma is rapidly increasing. 1, 3 Tobacco, alcohol consumption, and Barrett's esophagus are among the major risk factors for esophageal cancer. The overall 5-year survival rate is approximately 20%, despite the development of multimodal therapies, including surgery, chemotherapy, radiotherapy, and chemoradiotherapy. Recent advances in immunotherapy suggest that blocking programmed death-1 (PD-1) signaling is a suitable treatment option in patients with advanced esophageal SCC. In addition, anti-cancer immune responses involving lymphocytes are significantly associated with improved clinical course in many cancers, including esophageal cancer. 4, 5 It is well known that a high density of tumor-infiltrating lymphocytes (TILs) in cancer tissues is associated with improved therapeutic responses and favorable overall survival in esophageal cancer. ; Nichirei, Tokyo, Japan), and anti-Iba1 antibody (rabbit polyclonal, WAKO, Tokyo, Japan) were used as primary antibodies. Following reaction with the primary antibodies, the samples were incubated with horseradish peroxidase-labeled goat anti-mouse or rabbit secondary antibodies (Nichirei). Immunoreactions were visualized using the diaminobenzidine (DAB) substrate system (Nichirei). For double immunostaining, sections visualized with DAB in the first immunostaining were treated by microwave with 1 mM EDTA solution, and then the second immunostaining was performed, with the reaction visualized using HistoGreen (Linaris). For scoring of CD169 and IDO1 expression, all samples were evaluated microscopically by two pathologists (H. T. and T. S., H. T. and K. O., respectively) who were blind to patient information. Samples were evaluated according to the scoring system reported by Allred et al., 22 which is used to evaluate hormone receptors in breast cancer, and the data were averaged for statistical analyses. The extent of CD8-positive lymphocyte infiltration into each area was graded from 1 (weak or absent) to 3 (extensive) by two pathologists (H. T. and Y. K.) who were blinded to patient information.
Macrophage culture and gene expression analysis
Peripheral blood mononuclear cells were obtained from healthy volunteer donors who had provided written informed consent for the use of their cells in accordance with the study protocols approved by the Kumamoto University Hospital Review Board (#1169). Monocytes were isolated using RessetteSep (Veritas), plated in UpCELL 6-well culture plates (5 Â 10 5 cells/well; CellSeed, Tokyo, Japan), and cultured in AIM-V medium (Thermo Fisher, Waltham, MA, USA) supplemented with 2% human serum, 1 ng/mL granulocyte macrophage-colony stimulating factor (WAKO, Tokyo, Japan), and 50 ng/mL macrophage-colony stimulating factor (WAKO) for 7 days to induce macrophage differentiation. Macrophages were detached once and replated in 6-well plates and cultured with cytokine-free medium for 1 day. Macrophages were then stimulated with either IL-6, IL-10, IFN-a, IFN-b, IFN-g (WAKO), or LPS (Sigma, St. Louis, MO, USA) for 1 day, at which time mRNA was isolated using RNAiso plus (Takara Bio Inc., Otsu, Shiga) according to the manufacturer's protocol. cDNA microarray analysis (SurePrint G3 Human Gene Expression Microarray; Agilent Technologies) was performed using a Cell Innovator (Fukuoka, Japan), and the resulting expression data were deposited in the NCBI Gene Expression Omnibus under accession number GSE11481. Total RNA was isolated using RNAiso Plus (Takara Bio Inc.) and reverse transcribed using was compared between two groups using the log-rank test. The median was used as the cutoff value for comparisons between two groups. As the data were non-parametric, the Mann-Whitney U and Kruskal-Wallis tests were used. A P-value of <0.05 was considered to represent a statistically significant difference.
RESULTS
Higher score of CD169þ sinus macrophages was associated with better clinical prognosis
We first performed immunostaining to investigate the expression of CD169 in RLNs obtained from esophageal cancer patients. As shown in Fig. 1a , the RLN sinus was clearly identified as an area filled with macrophages, and CD169 expression in LySMs was found to vary in each patient. Two independent pathologists evaluated the expression of CD169 in non-metastatic RLNs using the scoring system described in the Materials and Methods, and the average of the total score of the two pathologists is noted as the final score. The distribution of final scores is shown in Fig. 1b , and cases with a score >4 were classified as "high" to divide the distribution of final scores equally. Statistical correlations between CD169 expression and clinicopathologic factors, including clinical prognosis, were then examined. High CD169 expression was more common in females as compared with males; however, there were no significant correlations with histologic subtype, T status, pretreatment, stage, or lymph nodes metastasis (Table 1) . Cancer-specific survival (CSS) was significantly longer in the high-CD169 group than that in the low-CD169 group among all cases (Fig. 1c, d , Table 2 ). However, no significant correlation was observed for relapse free survival (RFS) (Fig. 1c, d , Table 3 ).
Higher score of CD8-positive T cells in tumor nests was associated with better clinical prognosis in patients who underwent pretreatment
Next, the infiltration of CD8-positive TILs in primary cancer tissues was investigated in all cases to assess the anticancer immune responses in patients. Since the density of CD8-positive TILs in cancer nests is more reflective of anti-cancer immune responses more than the density in the stroma and invasive front, the density of TILs in cancer nest was classified as 1 (low), 2 (intermediate), or 3 (high), as shown in Fig. 2a . A total of 85 cases had a score of 1, 29 had a score of 2, and 26 had a score of 3. The cases were then classified into two groups (CD8 high, score of 2 or 3; CD8 low, score of 1). Although the density of TILs in nests was not associated with RFS or CSS (Figs. 1c, 2b) , a correlation between TIL density and CSS was observed when the statistical analysis was restricted to patients who underwent pretreatment (Fig. 2b) . The density of TILs was higher in CD169 high patients in the pretreatment (þ) group; however, no significant correlation was observed in the pretreatment (À) group (Fig. 2c, d ).
IDO1 and CD169 expression were linked to M1-like activation of human macrophages
We attempted to identify a more useful marker for evaluating the anti-cancer activation status of LySMs in addition to CD169. As it was clearly established in a previous study that CD169 is up-regulated by LPS and IFNs and downregulated by IL-10 and IL-6, we identified genes for which the expression changed similarly to CD169. Macrophages were initially stimulated with or without IFN-a and IL10, and then gene expression of selected genes was analyzed (Fig. 3a) . The focus of the analysis was genes encoding immune-related molecules, and we finally identified IDO1. The expression pattern of IDO1 in macrophages was evaluated using qPCR analysis of macrophages stimulated with various cytokines and LPS. As shown in Fig. 3b , IDO1 expression increased significantly following stimulation with IFNs and LPS and decreased following stimulation with IL-6 and IL-10. This expression pattern was similar to that of CD169.
IDO1 expression in LySMs was associated with CD169 expression but not correlated with TILs or clinical prognosis
IDO1 expression was detected in LySMs in LNs, and the staining score was evaluated in addition to CD169 scoring (Fig. 4a) . The distribution of final scores is shown in Fig. 4b , and cases with a score >1.5 were classified as "high" to divide the cases into two groups. There was no significant association between IDO1 expression and clinicopathologic factors, including clinical prognosis (Fig. 4c, Tables 1-3 ).
There was a significant positive correlation between CD169 score and IDO1 score in LySMs, but no significant correlation with the density of TILs was observed (Fig. 4d) . Double immunostaining of Iba1 (a marker for pan-macrophages) and IDO1 showed that LySM expressed IDO1 (Fig. 4e) ; however, double immunostaining of CD169 and IDO1 indicated that IDO1-positive cells differ from CD169-positive LySM (Fig. 4f) .
DISCUSSION
In this study, we found that LySMs play a significant role in anti-cancer immune responses in patients with esophageal cancer. In particular, high expression of CD169 in LySMs was associated with a high density of TILs and better clinical prognosis in patients who underwent pretreatment.
Research in the last decade has suggested the importance of an M1/M2 balance in the macrophage phenotype, [23] [24] [25] and CD169 has been suggested as a marker of the M1-like phenotype, as its expression is induced by IFN-related signals. 26 We previously suggested that a high IFN signature in primary cancer lesions or RLNs results in overexpression of CD169 in LySMs. 27 As the antigenpresenting capacity is considered to be stronger in the M1-like phenotype compared with the M2-like phenotype, CD169-positive LySMs could be characterized as M1-like phenotype. Together with our previous studies, the present findings show that the CD169 expression in LySM varies considerably in patients, although the number of total LySM remains approximately constant. Before deciding to focus on the RLNs closest to the main primary cancer lesion in the present study, we investigated whether CD169 expression in LySM was similar to that in other RLNs in 9 CD169-postive cases. The result showed that CD169 expression in LySM was similar in other esophageal RLNs, which was consistent with our previous findings. 28 Therefore, we considered it unnecessary to check all RLNs when evaluating CD169 expression in LySM.
The density of TILs in cancer tissues has been evaluated based on "immunoscores" in recent years, and this is expected to become a new component for the classification of cancer following TMN classification. 29 In colorectal cancer, it has long been known that a high density of TILs is associated with a better clinical course, 30 and recent findings of a meta-analysis of 250 published articles indicated a similar association. 31 A meta-analysis of 22 studies indicated that patients with a high density of TILs showed a significantly more-favorable clinical course in esophageal cancer patients. 32 In this study, we demonstrated that a high density of TILs is associated with better clinical course in patients who underwent pretreatment. Therefore, we propose that the immunoscore of TILs would be particularly useful for predicting the clinical course in patients undergoing pretreatment. With regard to the association between CD169 and TILs, a significant association was found in patients who underwent neoadjuvant chemotherapy but not in patients without pretreatment. Cancer cells killed by chemotherapy are thought to be translocated to RLNs and engulfed by LySMs and dendritic cells, which then induce the immune reactions of lymphocytes. Our previous animal model study suggested that local inflammation in primary cancer tissues influences the expression of CD169 in LySMs. 33 Our results also suggested that IFN-alpha produced by plasmacytoid DCs affects the expression of CD169 in LySMs. 34 An analysis of the relationship between immunogenic cancer cell death, high IFN signatures, and CD169 expression in patients undergoing pretreatment might be of interest.
In the present study, we also tried to identify a more prognostic marker of LySMs than CD169. As CD169 is known to be elevated in human macrophages following stimulation with IFNs (especially IFN-a) but not IL-10, we evaluated various immune-related genes using microarray analysis of human macrophages stimulated with IFN-a or IL-10 and identified IDO1 and LAG3 (Fig. 3) . LAG3 expression was detected in lymphocytes but not LySMs, whereas IDO1 expression was detected in LySMs but not lymphocytes. Therefore, we investigated IDO1 expression in cultured macrophages and tissue sections. A significant positive correlation between IDO1 and CD169 expression in LySMs was observed; however, IDO1 expression was not associated with any clinicopathologic factors. These data indicate that CD169 is more predictive of a better clinical prognosis and high anti-cancer immune activity than IDO1. Although the literature contains many research articles related to IDO1 in cancer, including esophageal cancer, [35] [36] [37] we believe the present report is the first to describe the expression of IDO1 in LySMs. IDO1 plays a critical role in promoting the immune evasion of cancer cells, 38 and recent clinical trials have focused on the anti-cancer effects of IDO1 inhibitors. 39, 40 The anti-cancer effects of IDO1
inhibitors could involve functional changes in LySMs.
The results of double immunostaining demonstrated that IDO1-positive LySMs are negative for CD169, indicating the heterogeneity of LySMs. Macrophages can be divided into two groups; resident macrophages and exudate macrophages. [41] [42] [43] Exudate macrophages are derived from circulating monocytes, whereas some resident macrophages originate from fetal yolk sac macrophages. [41] [42] [43] It has been proposed that whether or not CD169-positive/-negative LySMs are resident, might affect IDO1 expression in LySM due to the high IFN signature in RLN. However, it is necessary to further elucidate the characteristics of LySM in the future studies.
In conclusion, we demonstrated that a high CD169 score is a prognostic factor in patients with esophageal cancer. The CD169 score was positively correlated with the density of TILs in patients who underwent neoadjuvant chemotherapy, indicating that high CD169 expression in LySMs might be involved in the induction of anti-cancer immune responses. We also found a significant correlation between CD169 and IDO1 expression in LySMs. The CD169 score in LySMs could be a useful marker for evaluating anticancer immune responses or the immune cycle in patients with esophageal cancer.
